Literature DB >> 10961861

How I treat older patients with AML.

E H Estey1.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10961861

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  19 in total

1.  Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.

Authors:  Stefan Faderl; Farhad Ravandi; Xuelin Huang; Xuemei Wang; Elias Jabbour; Guillermo Garcia-Manero; Tapan Kadia; Alessandra Ferrajoli; Marina Konopleva; Gautam Borthakur; Jan Burger; Jennie Feliu; Hagop M Kantarjian
Journal:  Cancer       Date:  2012-01-26       Impact factor: 6.860

2.  Trends in the treatment of acute myeloid leukaemia in the elderly.

Authors:  Kathleen Lang; Craig C Earle; Talia Foster; Deirdre Dixon; Renilt Van Gool; Joseph Menzin
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

3.  Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.

Authors:  Elias Jabbour; Guillermo Garcia-Manero; Jorge Cortes; Farhad Ravandi; William Plunkett; Varsha Gandhi; Stefan Faderl; Susan O'Brien; Gautam Borthakur; Tapan Kadia; Jan Burger; Marina Konopleva; Mark Brandt; Xuelin Huang; Hagop Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-04-24

4.  Prognostic risk score for the survival of elderly patients with acute myeloid leukaemia comprising comorbidities.

Authors:  Irena Djunic; Nada Suvajdzic-Vukovic; Marijana Virijevic; Aleksandra Novkovic; Natasa Colovic; Ana Vidovic; Dragica Tomin
Journal:  Med Oncol       Date:  2012-12-29       Impact factor: 3.064

5.  Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome.

Authors:  D Modi; A Deol; S Kim; L Ayash; A Alavi; M Ventimiglia; D Bhutani; V Ratanatharathorn; J P Uberti
Journal:  Bone Marrow Transplant       Date:  2017-09-04       Impact factor: 5.483

Review 6.  Older adults with acute myeloid leukemia.

Authors:  Mikkael A Sekeres; Richard Stone
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

Review 7.  Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments.

Authors:  Jeffrey C Bryan; Elias J Jabbour
Journal:  Drugs Aging       Date:  2015-08       Impact factor: 3.923

8.  Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.

Authors:  Mikkael A Sekeres; Paul Elson; Matt E Kalaycio; Anjali S Advani; Edward A Copelan; Stefan Faderl; Hagop M Kantarjian; Elihu Estey
Journal:  Blood       Date:  2008-09-30       Impact factor: 22.113

9.  Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposide.

Authors:  Hisashi Tsurumi; Nobuhiro Kanemura; Takeshi Hara; Senji Kasahara; Toshiki Yamada; Michio Sawada; Masami Oyama; Hisataka Moriwaki
Journal:  J Cancer Res Clin Oncol       Date:  2007-04-24       Impact factor: 4.553

10.  Standard intensive chemotherapy is less effective and far more toxic than attenuated induction and post-induction regimen in elderly patients with acute myeloid leukemia.

Authors:  Bin-Tao Huang; Wei-Hong Zhao; Qing-Chun Zeng; Bing-Sheng Li; Rui-lin Chen
Journal:  Med Oncol       Date:  2014-04-18       Impact factor: 3.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.